<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771146</url>
  </required_header>
  <id_info>
    <org_study_id>012-180</org_study_id>
    <nct_id>NCT01771146</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer</brief_title>
  <official_title>A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic&#xD;
      pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pancreas cancer will be enrolled and treated with a planned course of 6 cycles&#xD;
      (3 months) of chemotherapy with FOLFIRINOX prior to undergoing surgical resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• The length of time from diagnosis (enrollment) to death</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Overall Survival rate defined by the % of people who are alive for a certain period of time after diagnosis</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• R0 resection as defined as microscopically negative margins</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Localized Pancreas Cancer</condition>
  <condition>Non-metastatic Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant FOLFIRINOX Regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX Regimen</intervention_name>
    <description>6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion</description>
    <arm_group_label>Neoadjuvant FOLFIRINOX Regimen</arm_group_label>
    <other_name>FOLFIRINOX</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>5-FU</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Male or non-pregnant and non-lactating female&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of pancreas&#xD;
&#xD;
          -  Patients must have satisfactory blood counts and blood chemistry levels at baseline&#xD;
             (refer to Appendix 2, Study Laboratory References Range).&#xD;
&#xD;
          -  Patient has Eastern Cooperative Oncology Group(ECOG) Performance Status 0 to 1 (refer&#xD;
             to Appendix 7):&#xD;
&#xD;
          -  0 - Asymptomatic (Fully active, able to carry on all predisease activities without&#xD;
             restriction)&#xD;
&#xD;
          -  1 - Symptomatic but completely ambulatory (Restricted in physically strenuous activity&#xD;
             but ambulatory and able to carry out work of a light or sedentary nature. For example,&#xD;
             light housework, office work)&#xD;
&#xD;
          -  Signed study consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years of age&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Patient has islet cell neoplasms&#xD;
&#xD;
          -  Patient has known brain metastases&#xD;
&#xD;
          -  Patient has metastatic disease&#xD;
&#xD;
          -  Active secondary malignancies&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Known infection with hepatitis B, hepatitis C, or cirrhosis&#xD;
&#xD;
          -  Major surgery or vascular device placement (excluding ports for IV&#xD;
             medication/chemotherapy) within 2 weeks prior to Day 1 of treatment in study&#xD;
&#xD;
          -  Prior chemotherapy or radiation for pancreatic cancer&#xD;
&#xD;
          -  History of allergy or hypersensitivity to the study drugs&#xD;
&#xD;
          -  Patient is enrolled in any outside (outside Baylor University Medical Center or Texas&#xD;
             Oncology) clinical protocol or investigational trial&#xD;
&#xD;
          -  Significant cardiac disease as defined as New York Heart Association (NYHA)&#xD;
             classification III or IV, uncontrolled congestive heart failure (CHF), or prior&#xD;
             myocardial infarction (MI) last 6-months&#xD;
&#xD;
          -  Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal&#xD;
             radiation which in the opinion of the investigator may place the patient at increased&#xD;
             risk&#xD;
&#xD;
          -  Peripheral sensory neuropathy ≥ to grade 2 at baseline&#xD;
&#xD;
          -  Significant co-morbidities deemed by investigator as unsuitable for&#xD;
             participation/enrollment&#xD;
&#xD;
          -  Study consent form not signed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Celinski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center - Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-metastatic Pancreas Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Cancer of Pancreas</keyword>
  <keyword>Adenocarcinoma of Pancreas</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

